KMT2A-CBL fusion in rapidly progressive myeloid disorder

Cancer Genet. 2022 Aug:266-267:90-92. doi: 10.1016/j.cancergen.2022.07.005. Epub 2022 Jul 28.

Authors

Manita Chaum¹, Eric Vail¹, Rhona Schreck¹, Jeremy Lorber², Celeste C Eno³

Affiliations

¹ Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
² Tower Hematology-Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
³ Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: celeste.eno@cshs.org.

PMID: 35933946
DOI: 10.1016/j.cancergen.2022.07.005

No abstract available

Keywords: AML-MRC; KMT2A deletion; KMT2A-CBL; MLL; Myeloid neoplasia.

Publication types

Case Reports

MeSH terms

Histone-Lysine N-Methyltransferase / genetics
Humans
Leukemia, Myeloid, Acute*
Myeloid-Lymphoid Leukemia Protein* / genetics
Oncogene Proteins, Fusion / genetics

Substances

Oncogene Proteins, Fusion
Myeloid-Lymphoid Leukemia Protein
Histone-Lysine N-Methyltransferase